drugset / Trial / NCT06721299
Clenbuterol to Target DUX4 in FSHD
Phase 1
Recruiting
30 enrolled
Jeffrey Statland
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · collabUniversity of Rochester · collabUniversity of Washington · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.
Timeline
- Start
- 2025-06-25
- Primary completion
- 2028-02
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clenbuterol | Small molecule | 20 ug | Oral |
| Subject | Clenbuterol | Small molecule | 40 ug | Oral |
| Subject | Clenbuterol | Small molecule | 60 ug | Oral |